MXPA06012321A - Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra. - Google Patents

Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra.

Info

Publication number
MXPA06012321A
MXPA06012321A MXPA06012321A MXPA06012321A MXPA06012321A MX PA06012321 A MXPA06012321 A MX PA06012321A MX PA06012321 A MXPA06012321 A MX PA06012321A MX PA06012321 A MXPA06012321 A MX PA06012321A MX PA06012321 A MXPA06012321 A MX PA06012321A
Authority
MX
Mexico
Prior art keywords
protein
modified
human
complement
fvc
Prior art date
Application number
MXPA06012321A
Other languages
English (en)
Spanish (es)
Inventor
Carl-Wilhelm Vogel
David C Fritzinger
Original Assignee
Univ Hawaii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Hawaii filed Critical Univ Hawaii
Publication of MXPA06012321A publication Critical patent/MXPA06012321A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
MXPA06012321A 2004-04-30 2005-04-29 Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra. MXPA06012321A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56706904P 2004-04-30 2004-04-30
US65324705P 2005-02-14 2005-02-14
US66735205P 2005-03-31 2005-03-31
PCT/US2005/015119 WO2005107785A2 (en) 2004-04-30 2005-04-29 Human complement c3 derivates with cobra venom factor-like function

Publications (1)

Publication Number Publication Date
MXPA06012321A true MXPA06012321A (es) 2007-04-19

Family

ID=35320733

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012321A MXPA06012321A (es) 2004-04-30 2005-04-29 Derivados c3 del complemento humano con funcion similar al factor de veneno de cobra.

Country Status (9)

Country Link
US (2) US8632780B2 (enExample)
EP (1) EP1755658A4 (enExample)
JP (1) JP2008502323A (enExample)
KR (1) KR20070036057A (enExample)
AU (1) AU2005240096A1 (enExample)
CA (1) CA2565227A1 (enExample)
IL (1) IL178905A0 (enExample)
MX (1) MXPA06012321A (enExample)
WO (1) WO2005107785A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003159A1 (en) 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
US8632780B2 (en) 2004-04-30 2014-01-21 University Of Hawaii Human complement C3 derivates with cobra venom factor-like function
WO2010056399A1 (en) * 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
RU2549468C2 (ru) * 2013-08-09 2015-04-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт нормальной физиологии имени П.К. Анохина" Российской академии медицинских наук (ФГБУ "НИИНФ им. П.К. Анохина" РАМН") Способ определения стабилизации с3-конвертазы классического пути активации комплемента человека
WO2015192101A1 (en) * 2014-06-12 2015-12-17 University Of Hawaii Uses of humanized cobra venom factor for reducing or preventing immunogenicity
US20190016766A1 (en) * 2015-10-07 2019-01-17 Daniel E. Benjamin Use of improved modulators of complement function as cancer therapeutics
US11903996B2 (en) * 2015-10-07 2024-02-20 David C. Fritzinger Modulators of complement function
CN106472354B (zh) * 2016-10-21 2019-05-31 新希望六和饲料股份有限公司 一种成年鸡用饲料盘
CN106472359B (zh) * 2016-10-21 2019-07-26 新希望六和饲料股份有限公司 一种1-3周龄雏鸡用饲料盘

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661347A (en) * 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
CA2160127A1 (en) * 1993-04-07 1994-10-13 David C. Fritzinger Dna encoding cobra c3, cvf1, and cvf2
US5714344A (en) * 1993-04-07 1998-02-03 Georgetown University Protease-derivatized CVF
WO1996007738A2 (en) * 1994-09-08 1996-03-14 Imutran Limited Modified human c3 proteins
US6221657B1 (en) * 1995-09-08 2001-04-24 Imutran Limited Modified human C3 DNA sequences and vectors
US5922320A (en) * 1996-06-14 1999-07-13 Georgetown University Recombinant proCVF
WO2005003159A1 (en) * 2003-07-03 2005-01-13 Koeln Johanna Complement depletion using recombinant human c3-derivatives
US8632780B2 (en) * 2004-04-30 2014-01-21 University Of Hawaii Human complement C3 derivates with cobra venom factor-like function
US20100179092A1 (en) * 2006-11-15 2010-07-15 Fritzinger David C Human complement c3 derivatives with cobra venom factor-like function

Also Published As

Publication number Publication date
CA2565227A1 (en) 2005-11-17
JP2008502323A (ja) 2008-01-31
US8632780B2 (en) 2014-01-21
US20080311132A1 (en) 2008-12-18
WO2005107785A3 (en) 2005-12-15
EP1755658A2 (en) 2007-02-28
WO2005107785A2 (en) 2005-11-17
US20080234191A1 (en) 2008-09-25
IL178905A0 (en) 2007-03-08
AU2005240096A1 (en) 2005-11-17
EP1755658A4 (en) 2008-11-05
KR20070036057A (ko) 2007-04-02

Similar Documents

Publication Publication Date Title
US20080234191A1 (en) Human complement C3 derivates with cobra venom factor-like function
US6057110A (en) Human hyaluronidase
JP5427409B2 (ja) 自己免疫疾患及び移植片拒絶反応を治療するためのＩｄｅＳプロテイナーゼ（化膿連鎖球菌由来）の使用
CZ20031718A3 (cs) Polypeptidická proteáza štěpící von Willebrandův faktor (vWF), nukleová kyselina kódující tento polypeptid a použití tohoto polypeptidu
KR20110114587A (ko) 세린 프로테아제 유도체 및 혈액응고 장애의 치료 또는 예방의 용도
US5849297A (en) Modified human C3 proteins
JP2001525666A (ja) ヒトセリンプロテアーゼ前駆体
JP2003515338A (ja) 補体結合酵素、ｍａｓｐ−３、及びその使用
US20100179092A1 (en) Human complement c3 derivatives with cobra venom factor-like function
CN1178950C (zh) 司登尼亚蛋白小体-司登尼亚钙蛋白
US6379913B1 (en) Human serine carboxypeptidase
JP2003313199A (ja) コラーゲン誘発血小板凝集抑制剤
RU2186110C2 (ru) Рекомбинантный белок asp-паллидипин, способ его производства и очистки, вектор, штамм, фармацевтическая композиция
Vogel et al. Cobra venom factor: the unique component of cobra venom that activates the complement system
US6221657B1 (en) Modified human C3 DNA sequences and vectors
JP2001515720A (ja) β−デフェンシン
JPH08511157A (ja) Ｘａファクター阻害活性を有する新規ポリペプチド
SK121798A3 (en) Native protein of a complement line, a fragment or variant of protein, dna sequence coding a protein, dna construct, a conjugate containing protein, pharmaceutical composition and use of protein
JP2023549878A (ja) 自己抗体に対する回避率又は活性が向上したａｄａｍｔｓ１３バリアント
JP2002501378A (ja) ヒト腫瘍関連Ｋａｚａｌインヒビタ
US7208311B2 (en) Catalytic domain of ADAM33 and methods of use thereof
JP2002526074A (ja) 新規のヒト肝臓癌誘導生長因子のコード配列、そのコードされるポリペプチド、およびこれらの製造方法。
JPH08510903A (ja) 蛭ヒルド・メディシナリスの組換えｘａ因子インヒビターの作製
CN101014362A (zh) 具眼镜蛇毒因子样功能的人补体c3衍生物
Tejada et al. Cloning of an avian antithrombin: developmental and hormonal regulation of expression

Legal Events

Date Code Title Description
FA Abandonment or withdrawal